German molecular diagnostics company Curetis has acquired the real-time qPCR-based Gyronimo Platform from Carpegen and Systec, the joint owners of the platform.
Gyronimo has been designed to provide results within an hour. The quantitative real-time PCR testing in a cartridge format provides up to ten parallel multiplex qPCR reactions from one sample.
Go deeper with GlobalData
Under the terms of acquisition agreement, Curetis will assume control over functional prototype of Gyronimo instruments and cartridges, and will complete the in vitro diagnostics development and industrialisation as well as OEM manufacturing of systems and cartridge production.
Curetis will acquire exclusive Gyronimo knowhow and a non-exclusive license to background intellectual property and know-how.
It will also assume exclusive worldwide rights to sublicense, partner or sell it, with an exemption for Carpegen and Systec in dental testing as well as in environmental and food safety testing.
See Also:
The acquisition will enable Curetis to integrate Gyronimo into the Unyvero Platform, which is a fast, comprehensive diagnostics system developed by Curetis for severe infectious diseases in hospitalised patients.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe integration will widen scopes of its product portfolio into areas such as infection control, viral testing and CNS infections, as well as applications for immunocompromised patients.
Curetis CEO Dr Oliver Schacht said: “Gyronimo’s advanced product development stage, its speed, quantitation ability, low cost of goods and mid-range multiplexing features are unique.
"It is therefore a natural next step in the development of our Unyvero Platform and we do not intend to develop it as a separate system, but rather as an integral and modular part of our overall Unyvero Solution.”
The company will make a one-time upfront payment of €5m in cash and additionally, Carpegen and Systec can gain two discrete, one-time milestone payments respectively totaling up to €2.5m, conditioned upon platform and first cartridge CE marking and US Food and Drug Administration (FDA) clearance.
